Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX

Progression-free survival and overall-free survival. A: Kaplan–Meier estimates for progression-free survival. B: Kaplan–Meier estimates for overall survival 1 (OS1 was defined as the time from the start date of FOLFIRINOX to the date of death for any reason; patients alive were censured at the last follow-up date). C: Kaplan–Meier estimates for overall survival 2 (OS2 was defined as the time from the start date of the second line to the date of death for any reason; patients alive were censured at the last follow-up date).